Anticoagulation for heart failure: selecting the best therapy.

Area of Science:

• Cardiology
• Geriatrics
• Neurology

Background:

• Heart failure (HF) is a prevalent condition in individuals over 65, representing a significant Medicare diagnosis.
• Despite advances in HF management, the risk of thromboembolic complications, particularly stroke, remains underestimated.
• Stroke is a major complication of HF, second only to atrial fibrillation in cardiogenic stroke causation.

Purpose of the Study:

• To highlight the underappreciated risk of stroke in heart failure patients.
• To review the current limitations of antithrombotic therapies in HF management.
• To emphasize the need for large-scale randomized trials on antithrombotic agents in HF.

Main Methods:

• Review of recent heart failure trials and epidemiological data on stroke incidence.
• Analysis of existing evidence on antithrombotic agents (warfarin, aspirin) in cardiovascular conditions.
• Identification of knowledge gaps in HF-specific antithrombotic research.

Main Results:

• Stroke incidence in recent HF trials ranges from 1.5% to 2.4% annually.
• Warfarin efficacy is established in other conditions but not extensively studied in HF.
• Aspirin use in HF trials has been linked to increased HF admissions, potentially interfering with ACE inhibitor effects.

Conclusions:

• There is a critical unmet need for evidence-based antithrombotic strategies in heart failure.
• Current antithrombotic options have limitations or potential adverse effects in HF patients.
• Large randomized trials are essential to guide clinical practice and reduce stroke risk in HF.